MENU
meeting with doctors and managers

Defining ‘Disease Modification’ for Plaque Psoriasis to Support Clinical Practice

Home/Defining ‘Disease Modification’ for Plaque Psoriasis to Support Clinical Practice

Case Study:

Helping to Define ‘Disease Modification’ for Plaque Psoriasis to Support Clinical Practice

 

The Client

Our client is dedicated to advancing the understanding and treatment of immune-mediated diseases, including plaque psoriasis (PP).

Background

Questions have been raised about whether PP could be controlled, modified, or even brought into remission, but the Psoriasis Area and Severity Index (PASI) has limited clinical utility due to its subjectivity and variability.

Opportunity

There was an opportunity to establish a clinically appropriate definition of disease modification (DM) for PP that could be utilized in clinical settings, improving treatment approaches and patient outcomes.

 

Approach

Triducive designed a Delphi approach to engage multi-disciplinary experts in psoriasis care from Europe and North America and reach consensus on a clinically relevant definition of disease modification for PP.

Our process

Step 1

A multi-disciplinary group of experts in psoriasis care in Europe and North America were facilitated to discuss disease control, remission, and modification. They created a set of 35 statements to be tested across a wider audience.

Step 2

A structured online survey was created and disseminated across Europe and North America to survey a larger base of experts. The online survey tested the strength of agreement that existed in relation to the statements developed by the steering group.

Step 3

The steering group reviewed the survey results and developed a consensus definition for PP disease modification and specification for measuring disease modification.

Step 4

A manuscript capable of peer-reviewed publication was developed and authored by the steering group. Triducive supported submission to the Journal of the European Academy of Dermatology and Venereology (JEADV).

Outcomes and Observations

63

responses achieved from psoriasis experts in Europe and North America

1

clear, clinically appropriate definition of Disease Modification for Plaque Psoriasis. And defined measurement criteria

JEADV

Published in a high impact peer-reviewed journal which supports credibility and citation of subsequent materials

>>

Provided a strong framework for long-term disease management and measurement in clinical settings, to be validated in real-world clinical environments

 

Testimonials

“This will hopefully transform patient care in the UK”
Consultant Respiratory Physician, UK
“I would like to express my deep gratitute for your team’s wonderful achievements”
Professor in Cardiovascular Immunology, South Korea
“They understand the scope of the work and what we are trying to achieve with what we're doing”
Professor of Pulmonary Medicine, Canada
“In my experience, you have done the most outstanding work”
Project Manager, Global Healthcare Company, Japan
“There is now so much weight of opinion that payers don’t have any reason to say 'no'”
Brand Director, Global Pharma Company, EU
“This will add to the evidence base that will inform future practice across the the EU”
Cardiothoracic Surgeon, Italy
“A great support to transform future surgery across the EU”
Chair, ETST
“This now provides clear focus in an area that has been confused for a long time”
Microbiologist, Germany
“We remember how unusually excellent you were in this project”
Global Medical Affairs Director, Global Pharma Company, UK
“A great piece of work”
Patient Organisation Leader
“They’ve managed to facilitate a publication in a really high impact journal that's gonna make a difference to the management of patients, not just for clinicians like me in the UK but also around the world”  
Professor of Renal Medicine, UK
“What a fantastic job you have all done”
Haematologist, UK

Sign up to our Newsletter